© 2022 MJH Life Sciences and Modern Retina. All rights reserved.
© 2022 MJH Life Sciences™ and Modern Retina. All rights reserved.
June 30, 2022
Dilsher Dhoot, MD, discusses the post hoc analysis of the Copernicus and Galileo trials, which investigated if a delay in treatment would affect visual acuity gains or change in anatomy.
June 29, 2022
Aleksandra Rachitskaya, MD, discussed the Phase 3 Archway end-of-trial results for the investigation of the Port Delivery System with ranibizumab in neovascular AMD.
June 28, 2022
Richard Rosen, MD, shares insights on how imaging can capture hyalocytes and their movement without the use of dyes.
June 24, 2022
An end-of-week review of retina news and stories from June 18 to June 24.
June 23, 2022
Steven Yeh, MD, provides a brief overview of available therapies for noninfectious uveitis and uveitis macular edema.
David Boyer, MD, discusses the Phase 3 investigation for OPT-302 combination therapy for wet AMD.
June 14, 2022
The study assesses retinal blood biomarkers using a new prototype OCT, aiming to measure retinal biomarkers such as blood flow volume, average velocity, and vessel diameter with a new prototype.
June 06, 2022
In the study, the faricimab molecule, which is a combined anti-Ang2 and anti-VEGF, performed better than the aflibercept drug in many different ways. Rishi P. Singh, MD, FASRS, summarizes some of these key findings.
June 02, 2022
Biogen and Samsung Bioepis announce the launch of ranibizumab-nuna and detail when the ophthalmic biosimilar will be available for retina specialists.
May 30, 2022
Yasha S. Modi, MD, discusses his best tips and tricks for finding and diagnosing infectious uveitis.